- Seelos Therapeutics Inc's SEEL Trehalose (SLS-005) has received Orphan Drug Designation for amyotrophic lateral sclerosis (ALS) from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP).
- Under the orphan designation, Seelos stands to benefit from several incentives such as protocol assistance, reduced regulatory fees, and market exclusivity.
- Price Action: SEEL shares are up 2.9% at $3.17 during the premarket session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareSmall CapFDAGeneralBriefsEuropean Medicines Agency (EMA)multiple sclerosisOrphan Drug Designation
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
